About this visual
Joe’s original visual on retatrutide efficacy, pain outcomes, and tolerability.
Sources & further reading
Original LinkedIn post and discussion ↗
Additional references appear in the infographic and the original LinkedIn discussion.

Originally posted Dec 2025 · By Joe Zucchi, PA-C, MPAS
1280 × 955 px · PDF includes the original image and a link to this page.
Joe’s original visual on retatrutide efficacy, pain outcomes, and tolerability.
Original LinkedIn post and discussion ↗
Additional references appear in the infographic and the original LinkedIn discussion.

A November 2026 overview of 12 investigational obesity therapies, spanning amylin-based treatments, GLP-1/GIP pathways, glucagon-containing combinations, and GLP-1 receptor agonists.

A six-slide overview of VK2735, covering injectable and oral Phase 2 results, exploratory maintenance dosing, dose-specific tolerability and Phase 3 programs.

A visual summary of sponsor-reported 80-week Phase 3 TRANSCEND-T2D-2 results comparing retatrutide with semaglutide 2 mg in adults with type 2 diabetes.
The Phase 3 TRIUMPH-4 data for Eli Lilly's retatrutide is out, and the results in patients with obesity and knee OA are very exciting. We're seeing incredible weight loss (mean reduction of 28.7% at the 12 mg dose) alongside a substantial ~76% improvement in WOMAC pain scores.
Beyond weight and pain, the cardiovascular marker improvements are noteworthy, including a decrease in systolic blood pressure of 14.0 mmHg at the highest dose.
As with any therapy, the tolerability profile is an important consideration. This infographic provides a snapshot of the key efficacy and safety data.